Medco: Follow-on biotech drugs could drive market growth

11/23/2008 | Reuters

Medco Health Solutions told investors Friday that follow-on biotech medicines could help the company and its customers save money if a regulatory pathway for such products is created. Assuming that an approval process would start in 2011, Amgen's Aranesp, Genentech's Avastin and Johnson & Johnson's Remicade would be among top-selling drugs that may face follow-on competition between 2013 and 2017, Medco said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN